Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 9/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 8/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 4/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580894 | 0.76 | HDAC2 (0.44) | — | |
| SCHEMBL14155908 | 0.73 | HDAC2 (0.44) | — | |
| SCHEMBL4580530 | 0.72 | MAPT (0.36) | HSD17B2HSD17B1 | |
| SCHEMBL31283785 | 0.71 | LMNA (0.41) | CYP3A4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL4578706 | 0.71 | ABCB1 (0.39) | — | |
| SCHEMBL4578712 | 0.71 | ABCB1 (0.39) | — | |
| SCHEMBL14155937 | 0.68 | ABCB1 (0.37) | ALOX5 | |
| SCHEMBL12889973 | 0.68 | SMYD2 (0.33) | CYP3A4 | |
| SCHEMBL6260193 | 0.68 | SMYD2 (0.35) | CYP3A4 | |
| SCHEMBL27831399 | 0.67 | KMO (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| EP-2007720-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2008-12-31 | — | — | EP | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HSD17B2 1159/4885HSD17B1 772/4885CYP2E1 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.